Dose-dependent effects of sildenafil on post-ischaemic left ventricular function in the rat isolated heart

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 3, 2010, Pages 346-351

  Kolettis, Theofilos M ^a,b   Kontaras, Konstantinos ^c   Spartinos, Ioannis ^c   Maniotis, Christos ^c   Varnavas, Varnavas ^a,c   Koutouzis, Michael ^c   Mourouzis, Iordanis ^d   Papalois, Apostolos ^b,e   Pantos, Constantinos ^d   Kyriakides, Zenon S ^b,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b Cardiovascular Research Institute   (Greece)

^c RED CROSS HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

^e ELPEN Research Laboratory   (Greece)

Author keywords

Ischaemia; Left ventricular function; Reperfusion; Sildenafil

Indexed keywords

SILDENAFIL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ENDDIASTOLIC PRESSURE; MALE; NONHUMAN; RAT; VOLKMANN CONTRACTURE;

ANIMALS; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART; ISCHEMIC CONTRACTURE; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RANDOM ALLOCATION; RATS; RATS, WISTAR; SULFONES; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 77950213867     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.03.0009     Document Type: Article

References (25)

1. Piper, HM, et al. A fresh look at reperfusion injury. Cardiovasc Res 1998 38 : 291 300.
2. Du Toit, EF, et al. Effect of nitrovasodilators and inhibitors of nitric oxide synthase on ischaemic and reperfusion function of rat isolated hearts. Br J Pharmacol 1998 123 : 1159 1167.
3. Du Toit, EF, et al. Relation of cyclic nucleotide ratios to ischemic and reperfusion injury in nitric oxide-donor treated rat hearts. J Cardiovasc Pharmacol 2001 38 : 529 538.
4. Steenbergen, C, et al. Correlation between cytosolic free calcium, contracture, ATP, and irreversible ischemic injury in perfused rat heart. Circ Res 1990 66 : 135 146.
5. Piper, HM, et al. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res 2004 61 : 365 371.
6. Boolell, M, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996 8 : 47 52.
7. Senzaki, H, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 2001 15 : 1718 1726.
8. Takimoto, E, et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 2005 96 : 100 109.
9. Nagayama, T, et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol 2009 53 : 207 215.
10. Du Toit, EF, et al. Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model. Cardiovasc Drugs Ther 2005 19 : 23 31.
11. Ockaili, R, et al. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 2002 283 : H1263 H1269.
12. Salloum, F, et al. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 2003 92 : 595 597.
13. Das, S, et al. Cardioprotection with sildenafil, a selective inhibitor of cyclic 3′,5′-monophosphate-specific phosphodiesterase 5. Drugs Exp Clin Res 2002 28 : 213 219.
14. Reffelmann, T. Kloner, RA. Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation. Cardiovasc Res 2003 59 : 441 449.
15. Kukreja, RC, et al. Sildenafil-induced cardioprotection in rabbits. Cardiovasc Res 2003 60 : 700 701.
16. Rossoni, G, et al. Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. Br J Pharmacol 2007 150 : 567 576.
17. El-Galley, R, et al. Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 2001 166 : 927 931.
18. Pantos, C, et al. Thyroxine pretreatment increases basal myocardial heat-shock protein 27 expression and accelerates translocation and phosphorylation of this protein upon ischaemia. Eur J Pharmacol 2003 478 : 53 60.
19. Perrin-Sarrado, C, et al. Release of secondary free radicals during post-ischaemic reperfusion is not influenced by extracellular calcium levels in isolated rat hearts. Mol Cell Biochem 2007 297 : 199 207.
20. Michelakis, E, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002 105 : 2398 2403.
21. Katz, SD, et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000 36 : 845 851.
22. Garcia-Dorado, D, et al. Selective inhibition of the contractile apparatus. A new approach to modification of infarct size, infarct composition, and infarct geometry during coronary artery occlusion and reperfusion. Circulation 1992 85 : 1160 1174.
23. Jackson, G, et al. Past present and future: a 7-year update of Viagra (sildenafil citrate). Int J Clin Pract 2005 59 : 680 691.
24. Vila-Petroff, MG, et al. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res 1999 84 : 1020 1031.
25. Preston, IR, et al. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir Med 2005 99 : 1501 1510.